The Nasopharyngeal Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Nasopharyngeal Cancer. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued products.

GlobalData tracks 157 drugs in development for Nasopharyngeal Cancer by 118 companies/universities/institutes. The top development phase for Nasopharyngeal Cancer is phase ii with 74 drugs in that stage. The Nasopharyngeal Cancer pipeline has 132 drugs in development by companies and 25 by universities/ institutes. Some of the companies in the Nasopharyngeal Cancer pipeline products market are: Jiangsu Hengrui Medicine, Novartis and TCR Cure Biopharma Technology.

The key targets in the Nasopharyngeal Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4).

The key mechanisms of action in the Nasopharyngeal Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with 19 drugs in Pre-Registration. The Nasopharyngeal Cancer pipeline products include 13 routes of administration with the top ROA being Intravenous and 16 key molecule types in the Nasopharyngeal Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.

Nasopharyngeal Cancer overview

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose, an area called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking including hoarseness, recurrent ear infections, face pain or numbness, headache, hearing loss, and ringing in the ears. Treatment includes surgery, chemotherapy, and radiation therapy.

For a complete picture of Nasopharyngeal Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.